BioNxt Solutions Inc. (BNXT) | Finanzwire

Basculer en Français

8296	Companies
114905	Keywords
55332	Articles
62461	Press releases

Headlines Articles Press releases BioNxt Solutions Inc.

Home
Companies
BioNxt Solutions Inc.

BRIEF

published on 07/17/2024 at 09:10, 4 months 4 days ago

BioNxt Signs Statement of Work with International CRDMO for Cladribine ODF Development

Multiple Sclerosis Pharmaceutical Development BioNxt Solutions Cladribine ODF CRDMO
PRESS RELEASE

published on 07/17/2024 at 09:05, 4 months 4 days ago

BioNxt Signs Statement of Work with International Contract Research, Development, And Manufacturing Organization for Cladribine ODF Development
BioNxt Solutions Inc. signs agreement with German CRDMO for Cladribine oral dissolvable film development program targeting the lucrative multiple sclerosis market

BioNxt Solutions Inc. Cladribine CRDMO Oral Dissolvable Film MS Market
BRIEF

published on 07/09/2024 at 09:10, 4 months 12 days ago

BioNxt Signs Master Services Agreement with International Contract Research, Development, and Manufacturing Organization

Drug Development Pharmaceutical Market Master Services Agreement BioNxt Solutions Cladribine ODF
PRESS RELEASE

published on 07/09/2024 at 09:05, 4 months 12 days ago

BioNxt Signs Master Services Agreement with International Contract Research, Development, and Manufacturing Organization
BioNxt Solutions Inc. signs master services agreement with German-based CRDMO for product development of oral dissolvable drug formulations

BioNxt Solutions Inc. Product Development Master Services Agreement CRDMO Oral Dissolvable Drug Formulations
BRIEF

published on 06/20/2024 at 01:05, 5 months 1 day ago

BioNxt Solutions Closes Second Tranche of Private Placement

Private Placement Common Shares Warrants Research Funding BioNxt Solutions
PRESS RELEASE

published on 06/20/2024 at 01:00, 5 months 1 day ago

BioNxt Solutions Announces Closing of Second Tranche of Non-Brokered Private Placement
BioNxt Solutions Inc. closes the second tranche of non-brokered private placement, raising $270,000. Proceeds will fund research, development, and working capital

Private Placement Common Shares Working Capital Research And Development BioNxt Solutions Inc.
BRIEF

published on 04/26/2024 at 05:55, 6 months 25 days ago

BioNxt Solutions Advances Cladribine Studies and Announces Financing Initiative

Private Placement BioNxt Solutions Inc. Multiple Sclerosis Cladribine Program Pharmaceutical Development
PRESS RELEASE

published on 04/26/2024 at 05:50, 6 months 25 days ago

Bionxt Solutions Announces Odf Cladribine Update and Financing
BioNxt Solutions Inc. advances Cladribine program to human bioavailability studies in Europe, targeting MS market. Announces private placement for research and development

Private Placement BioNxt Solutions Inc. Cladribine Program Bioavailability Studies Multiple Sclerosis Market
BRIEF

published on 03/18/2024 at 08:10, 8 months 3 days ago

BioNxt Advances Towards Human Trials with ODF Cladribine for MS

Clinical Trials BioNxt Solutions Inc. Multiple Sclerosis Drug Delivery Technology Pharmaceutical Market
PRESS RELEASE

published on 03/18/2024 at 08:05, 8 months 3 days ago

BioNxt Reports Commercialization of ODF Cladribine Product for MS Next Steps
BioNxt Solutions Inc. reports progress in toxicity and PK studies, advancing towards human comparative bioavailability studies. Development includes technology transfer, upscaling, & clinical sample prep for bioequivalence study

BioNxt Solutions Inc. Toxicity Studies Comparative Pharmacokinetic Studies Bioavailability Pharmaceutical Drug Market

Accesswire

Published on 11/21/2024 at 13:30, 32 minutes ago

AirIQ Announces September 30, 2024 Quarterly Results Company Reports Double-Digit Growth in Recurring Revenue
Published on 11/21/2024 at 13:30, 32 minutes ago

Datametrex Secures Additional P.O. Approx $250K for IT Services
Published on 11/21/2024 at 13:00, 1 hour 2 minutes ago

Aclara Secures Funding from Corfo's Innovation High-Tech Program for Artificial Intelligence Project
Published on 11/21/2024 at 13:00, 1 hour 2 minutes ago

Telomir Pharmaceuticals Confirms Age Reversal, Increased Longevity and Improved Healthspan in Groundbreaking Preclinical Study with Telomir-1
Published on 11/21/2024 at 13:00, 1 hour 2 minutes ago

Toggle3D.ai Rebrands as FOTOgpt.ai to Usher in a New Age of AI-Powered Photography

View all ACCESSWIRE

EQS Group

Published on 11/21/2024 at 13:15, 47 minutes ago

NOTICE OF ANNUAL GENERAL MEETING
Published on 11/21/2024 at 12:35, 1 hour 27 minutes ago

audius with successful third quarter 2024 - total revenue grows by +9.2% and EBITDA by +14.6
Published on 11/21/2024 at 12:15, 1 hour 47 minutes ago

Hardman & Co Investor Forum Research on Shield Therapeutics (STX): Proactive cash management to cashflow-breakeven
Published on 11/21/2024 at 12:06, 1 hour 56 minutes ago

IVU AG publishes Quarterly Report Q3-2024
Published on 11/21/2024 at 12:00, 2 hours 2 minutes ago

Holding(s) in Company

Les Echos

Published on 11/21/2024 at 06:58, 7 hours 4 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 18 hours 42 minutes ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 20 hours 17 minutes ago

MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 20 hours 17 minutes ago

Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
Published on 11/20/2024 at 07:45, 1 day 6 hours ago

Gimv sells to Fremman Capital a majority stake in outpatient rehabilitation specialist rehaneo

View all LES ECHOS COMFI WIRE